Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - DUSA Pharmaceuticals, Inc (NasdaqNM:DUSA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 13Earnings Announcement
Location
25 Upton Drive
Wilmington, MA 01887
Phone: (978) 657-7500
Email: lovells@dusapharma.com
Employees (last reported count): 41
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 66%
·Over the last 6 months:
 · one insider sell; 9,000  shares
·Institutional: 61% (178% of float)
(89 institutions)
·Net Inst. Selling: 1.15M shares (+15.98%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
DUSA Pharmaceuticals, Inc. is a pharmaceutical company developing drugs in combination with light devices to treat or detect a variety of conditions in processes known as photodynamic therapy or photodetection. The Company is engaged primarily in the research and development of its first drug, Levulan brand of aminolevulinic acid HCl (ALA) with light, for use in a broad range of medical conditions. Levulan Kerastick 20% Topical Solution with PDT uses the Company's first light device product, called the BLU-U, for the treatment of actinic keratoses (AKs) of the face or scalp. AKs are precancerous skin lesions caused by chronic sun exposure.
More from Market Guide: Expanded Business Description

Financial Summary
DUSA Pharmaceuticals Inc. is a development stage pharmaceutical company engaged in the development of photodynamic therapy and photodiagnosis utilizing 5-aminolevulinic acid for various medical indications. For the six months ended 6/30/01, revenues totaled $2.7 million, up from $603 thousand. Net loss rose 5% to $2.8 million. Revenues reflect the launch of products and research grants. Higher loss reflects increased R&D expenses due to higher personnel costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

D. Geoffrey Shulman, M.D., 46
Chairman, Pres, CEO
$484K--  
John Mattern, 52
CFO, VP-Fin.
--  --  
Ronald Carroll, 52
Exec. VP, COO
289K$597K
Stuart Marcus, M.D., Ph.D., 54
Sr. VP of Scientific Affairs and CSO
299K--  
Mark Carota, 45
VP-Operations
175K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DUSAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$9.438
Recent Price$10.98 
52-Week High
on 27-Sep-2000
$32.75 
Beta1.43 
Daily Volume (3-month avg)49.4K
Daily Volume (10-day avg)58.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-62.6%
52-Week Change
relative to S&P500
-49.9%
Share-Related Items
Market Capitalization$151.5M
Shares Outstanding13.8M
Float4.70M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.84 
Earnings (ttm)-$0.49 
Earnings (mrq)-$0.11 
Sales (ttm)$0.31 
Cash (mrq)$4.97 
Valuation Ratios
Price/Book (mrq)2.86 
Price/EarningsN/A 
Price/Sales (ttm)35.64 
Income Statements
Sales (ttm)$4.23M
EBITDA (ttm)-$10.6M
Income available to common (ttm)-$6.67M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-8.87%
Return on Equity (ttm)-12.09%
Financial Strength
Current Ratio (mrq)39.39 
Debt/Equity (mrq)0 
Total Cash (mrq)$68.5M
Short Interest
As of 8-Aug-2001
Shares Short652.0K
Percent of Float13.9%
Shares Short
(Prior Month)
624.0K
Short Ratio19.76 
Daily Volume33.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.